Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections

Acta Ophthalmologica

Volumn 89, Issue 1, 2011, Pages 70-75

  Meyer, Carsten H ^a   Michels, Stephan ^c,d   Rodrigues, Eduardo B ^e   Hager, Annette ^f   Mennel, Stefan ^b   Schmidt, Jörg C ^b   Helb, Hans Martin ^a,g   Farah, Michel E ^e  

^a UNIVERSITY OF BONN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Avastin Data Base Bonn   (Germany)

^d TRIEMLI HOSPITAL   (Switzerland)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f Asklepios Hospital North   (Germany)

^g House of Thousand Windows   (Germany)

Author keywords

adverse events; iatrogenic damage; intravitreal injection; needle; ora serrata; rhegmatogenous retinal detachments

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INCIDENCE; INJECTION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETINA DETACHMENT; RISK REDUCTION; VITRECTOMY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; IATROGENIC DISEASE; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETINAL DETACHMENT; RETINAL VEIN OCCLUSION; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79551510841     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02064.x     Document Type: Article

References (38)

1. Angulo Bocco MC, Glacet-Bernard A, Zourdani A, Coscas G, &, Soubrane G, (2008): Intravitreous injection: retrospective study on 2028 injections and their side effects. J Fr Ophtalmol 31: 693-698.
2. Anijeet DR, Hanson RJ, Bhagey J, &, Bates RA, (2007): National survey of the technique of intravitreal triamcinolone injection in the United Kingdom. Eye 21: 480-486.
3. Arevalo JF, Maia M, Flynn HW Jr, et al. (2008): Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92: 213-216.
4. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, &, Schneider S,; ANCHOR Study Group (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
5. Chan CK, Abraham P, Meyer CH, Kokame GT, et al. (2010): Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 30: 203-211.
6. Cintra LP, Lucena LR, Da Silva JA, Costa RA, Scott IU, &, Jorge R, (2009): Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging 40: 13-18.
7. Clemens CR, Holz FG, &, Meyer CH, (2010): Macular hole formation in the presence of a pigment epithelial detachment after three consecutive intravitreal antivascular endothelial growth factor injections. J Ocul Pharmacol Ther 26: 297-299.
8. Fung AE, Rosenfeld PJ, &, Reichel E, (2006): The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344-1349.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. (2004): VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
10. Jager RD, Aiello LP, Patel SC, &, Cunningham ET Jr, (2004): Risks of intravitreous injection: a comprehensive review. Retina 24: 676-698.
11. Jaissle GB, Szurman P, Feltgen N, et al.; Retinal Vein Occlusion Study Group (2010): Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (accepted)
12. Jonas JB, Spandau UH, &, Schlichtenbrede F, (2008): Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 22: 590-591.
13. Knecht PB, Michels S, Sturm V, Bosch MM, &, Menke MN, (2009): Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina 29: 1175-1181.
14. Kozak I, Dean A, Clark TM, Falkenstein I, &, Freeman WR, (2006): Prefilled syringe needles versus standard removable needles for intravitreous injection. Retina 26: 679-683.
15. Kuppermann BD, Thomas EL, de Smet MD, &, Grillone LR,; Vitrase for Vitreous Hemorrhage Study Groups (2005): Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 140: 585-597.
16. Magalhães O Jr, de Avila MP, Maia M, Nosé R, Costa EF, Rodrigues EB, Farah ME, &, Nosé W, (2010): Difference between bevel-up and bevel-down 23-gauge one-step incisions: analysis of anterior chamber optical coherence tomography and IOP. Retina 30: 521-523.
17. Mennel S, Meyer CH, &, Callizo J, (2010): Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmol 88: 610-613.
18. Meyer CH, Ziemssen F, &, Heimann H, (2008a): Intravitreal injection. Monitoring to avoid postoperative complications. Ophthalmologe 105: 143-157.
19. Meyer CH, Scholl HP, Eter N, Helb HM, &, Holz FG, (2008b): Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 86: 490-494.
20. Meyer CH, Rodrigues EB, Michels S, Mennel S, Schmidt JC, Martinazzo M, Helb HM, &, Farah ME, (2010): Incidence of damages to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 26: 491-495.
21. Meyer CH, Liu Z, Brinkmann CK, Rodrigues EB, &, Helb HM, (2011): Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0 cc syringe. Acta Ophthalmol (accepted).
22. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, Covarrubias P, Dominguez F, &, Sanchez-Huerta V, (2007): Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol 22: 109-125.
23. Rodrigues EB, Meyer CH, Schmidt JC, &, Kroll P, (2004): Unsealed sclerotomy after intravitreal injection with a 30-gauge needle. Retina 24: 810-812.
24. Rodrigues EB, Meyer CH, Grumann A Jr, Shiroma H, Aguni JS, &, Farah ME, (2007): Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol 143: 1035-1037.
25. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, &, Kim RY,; MARINA Study Group (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
26. Rutnin U, &, Schepens CL, (1967): Fundus appearance in normal eyes. II. The standard peripheral fundus and developmental variations. Am J Ophthalmol 64: 840-852.
27. Sarrafizadeh R, Hassan TS, Ruby AJ, Williams GA, Garretson BR, Capone A Jr, Trese MT, &, Margherio RR, (2001): Incidence of retinal detachment and visual outcome in eyes presenting with posterior vitreous separation and dense fundus-obscuring vitreous hemorrhage. Ophthalmology 108: 2273-2278.
28. Shima C, Sakaguchi H, Gomi F, et al. (2008): Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86: 372-376.
29. de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, &, Kampik A, (2009): Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 116: 1349-1355.
30. Smiddy WE, Michels RG, &, Green WR, (1991): Lens and peripheral retinal relationships during vitrectomy. Retina 11: 199-203.
31. Straatsma BR, Landers MB, &, Kreiger AE, (1968): The ora serrata in the adult human eye. Arch Ophthalmol 80: 3-20.
32. Taskintuna I, Rahhal FM, Rao NA, et al. (1997): Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 104: 1827-1837.
33. Tranos P, Gemenetzi M, Papandroudis A, Chrisafis C, &, Papadakos D, (2008): Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin. Eye 22: 862.
34. Wang J, McLeod D, Henson DB, &, Bishop PN, (2003): Age-dependent changes in the basal retinovitreous adhesion. Invest Ophthalmol Vis Sci 44: 1793-1800.
35. White MH, Lambert HM, Kincaid MC, Dieckert JP, &, Lowd DK, (1989): The ora serrata and the spiral of Tillaux. Anatomic relationship and clinical correlation. Ophthalmology 96: 508-511.
36. Wimpissinger B, &, Binder S, (2007): Entry-site-related retinal detachment after pars plana vitrectomy. Acta Ophthalmol Scand 85: 782-785.
37. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, &, Blumenkranz MS, (2008): Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 28: 1151-1158.
38. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al.; for the Pan American Collaborative Retina Group (PACORES) (2007): Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81-87.